Paper39640222
Mechanisms and implications of recompensation in cirrhosis.
Piano S and 2 others. JHEP Rep, 2024. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Mechanisms and implications of recompensation in cirrhosis. Papers, record 39640222. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39640222
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38218352 | Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient. | J Hepatol | 2024 | https://conductscience.org/library/papers/38218352 | PubMed |
| 2 | 16603731 | Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. | Am J Physiol Gastrointest Liver Physiol | 2006 | https://conductscience.org/library/papers/16603731 | PubMed |
| 3 | 10744587 | Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. | Ann Intern Med | 2000 | https://conductscience.org/library/papers/10744587 | PubMed |
| 4 | 29750389 | Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. | Liver Int | 2018 | https://conductscience.org/library/papers/29750389 | PubMed |
| 5 | 37035457 | Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis. | JHEP Rep | 2023 | https://conductscience.org/library/papers/37035457 | PubMed |
| 6 | 31607677 | Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/31607677 | PubMed |
| 7 | 35120736 | Baveno VII - Renewing consensus in portal hypertension. | J Hepatol | 2022 | https://conductscience.org/library/papers/35120736 | PubMed |
| 8 | 38478755 | Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series. | Hepatology | 2024 | https://conductscience.org/library/papers/38478755 | PubMed |
| 9 | 37151732 | Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension. | JHEP Rep | 2023 | https://conductscience.org/library/papers/37151732 | PubMed |
| 10 | 33544313 | Regression of portal hypertension: underlying mechanisms and therapeutic strategies. | Hepatol Int | 2021 | https://conductscience.org/library/papers/33544313 | PubMed |
| 11 | 25500203 | KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. | Gut | 2015 | https://conductscience.org/library/papers/25500203 | PubMed |
| 12 | 33746085 | A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. | J Hepatol | 2021 | https://conductscience.org/library/papers/33746085 | PubMed |
| 13 | 32535060 | Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. | J Hepatol | 2020 | https://conductscience.org/library/papers/32535060 | PubMed |
| 14 | 36481475 | Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. | Clin Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36481475 | PubMed |
| 15 | 33930587 | Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience. | Clin Res Hepatol Gastroenterol | 2021 | https://conductscience.org/library/papers/33930587 | PubMed |
| 16 | 8444409 | Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. | Hepatology | 1993 | https://conductscience.org/library/papers/8444409 | PubMed |
| 17 | 17335931 | Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. | J Hepatol | 2007 | https://conductscience.org/library/papers/17335931 | PubMed |
| 18 | 31426090 | Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. | Ann Intern Med | 2019 | https://conductscience.org/library/papers/31426090 | PubMed |
| 19 | 29861076 | Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. | Lancet | 2018 | https://conductscience.org/library/papers/29861076 | PubMed |
| 20 | 11079009 | Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. | Arch Pathol Lab Med | 2000 | https://conductscience.org/library/papers/11079009 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42706038 | [Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42706038 | PubMed |
| 42694603 | From fibrosis regression to recompensation: bibliometric and clinical evidence mapping of disease modification in cirrhosis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42694603 | PubMed |
| 42564337 | Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation. | Hepatol Forum | 2026 | https://conductscience.org/library/papers/42564337 | PubMed |
| 42544833 | Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis - To Suppress or Not to Suppress? | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42544833 | PubMed |
| 42455326 | Periportal hyperintensity sign on Gd-BOPTA-enhanced hepatobiliary phase MRI identifies patients less likely to achieve recompensation in decompensated cirrhosis. | Abdom Radiol (NY) | 2026 | https://conductscience.org/library/papers/42455326 | PubMed |
| 42355650 | CT-Quantified Sarcopenic Visceral Obesity Is Negatively Associated with Recompensation in Patients with Decompensated Cirrhosis: A Retrospective Single-Center Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/42355650 | PubMed |
| 42171974 | Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child-Turcotte-Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression. | Hepatol Int | 2026 | https://conductscience.org/library/papers/42171974 | PubMed |
| 42151601 | Comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection". | J Gastroenterol | 2026 | https://conductscience.org/library/papers/42151601 | PubMed |
| 41811796 | Recompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges. | Can J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41811796 | PubMed |
| 41635624 | Reply to: "Predicting the need for early TIPS in patients with cirrhosis and ascites: More art than science". | JHEP Rep | 2025 | https://conductscience.org/library/papers/41635624 | PubMed |
| 41622173 | Recompensation following first decompensation in patients with alcohol-related cirrhosis. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/41622173 | PubMed |
| 41589688 | Long-Term Outcomes After Endoscopic Sequential Therapy in Patients With Gastroesophageal Variceal Bleeding as the First Decompensated Event. | Clin Transl Gastroenterol | 2026 | https://conductscience.org/library/papers/41589688 | PubMed |
| 41528438 | Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis. | J Gastroenterol | 2026 | https://conductscience.org/library/papers/41528438 | PubMed |
| 41236657 | Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis. | Eur Radiol | 2026 | https://conductscience.org/library/papers/41236657 | PubMed |
| 41226066 | Diagnosis of Portal Hypertension. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41226066 | PubMed |
| 41204950 | Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection. | J Gastroenterol | 2026 | https://conductscience.org/library/papers/41204950 | PubMed |
| 41147778 | Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis. | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/41147778 | PubMed |
| 40873069 | [Clinical research progress in different stages of recompensated cirrhosis]. | Zhonghua Gan Zang Bing Za Zhi | 2025 | https://conductscience.org/library/papers/40873069 | PubMed |
| 40556980 | Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis. | Cureus | 2025 | https://conductscience.org/library/papers/40556980 | PubMed |
| 39870944 | Preventing the progression of cirrhosis to decompensation and death. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39870944 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39640222
GET https://conductscience.org/api/papers/v1/39640222/references?page=2